Search

Displaying results 1341 - 1350 of 10000 in total
  1. Drug

    Everolimus

    go.drugbank.com/drugs/DB01590
    ApprovedInvestigational

    In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein. … It is currently used as an immunosuppressant to prevent rejection of organ transplants.

    Products: EVEROLIMUS EG, VOTUBİA 5 MG TABLET, 100 ADET
  2. Drug

    Riboflavin

    go.drugbank.com/drugs/DB00140
    ApprovedInvestigationalNutraceuticalVet approved

    It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide. … Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast.

    Synonyms: Vitamin G, 1-Deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitolMixtures: B Plus C 300 mg, MOL-IRON PANEM 500 MG
  3. Drug

    Triptorelin

    go.drugbank.com/drugs/DB06825
    ApprovedInvestigationalVet approved

    Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. … After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis.

    Products: Triptofem 0,1 mg/ml Injektionslösung in einer Fertigspritze, Decapeptyl Depot - Retardmikrokapseln und Suspensionsmittel in Einmalspritzen
  4. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

    Products: Vocabria 400 mg/2 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET, Vocabria 600 mg/3 ml Enjeksiyonluk Uzatılmış Salımlı Süspansiyon, 1 ADET
  5. Drug

    Promazine

    go.drugbank.com/drugs/DB00420
    ApprovedVet approvedWithdrawn

    It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States.

    Synonyms: N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine, N-(3-Dimethylaminopropyl)phenothiazineProducts: PROMAZINA EG, Promazine HCl Inj 50mg/ml
  6. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    Tenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil]. … [A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil.

    Mixtures: DESCOVY (200/10 MG), DESCOVY (200/25 MG)Categories: Antivirals used in combination for the treatment of HIV infections, Vitamin B Complex
  7. Drug

    Bumetanide

    go.drugbank.com/drugs/DB00887
    ApprovedInvestigational

    Bumetanide is a sulfamyl diuretic.

    Mixtures: BURINEX TABLET 1 mg, BURINEX TABLET 1 mgProducts: BURINEX INJECTION 0.5 mg/ml, Burinex 2 mg - Ampullen
  8. Drug

    Evolocumab

    go.drugbank.com/drugs/DB09303
    ApprovedInvestigational

    Evolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … Evolocumab is the second PCSK9 inhibitor on the market, first being alirocumab.

    Products: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)
  9. Drug

    Diazoxide

    go.drugbank.com/drugs/DB01119
    ApprovedInvestigational

    In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates. … [A255647,L44612] In March 2025, an extended-release formulation of diazoxide choline was approved by the FDA for the treatment of hyperphagia in patients with Prader-Willi syndrome, becoming the first

    Categories: Arteriolar Smooth Muscle, Agents Acting OnProducts: AZOXID® 50 MG/ML SUSPENSION ORAL, UPGLYCEM® 50 MG/ML. SUSPENSIÓN ORAL
  10. Drug

    4SC-203

    go.drugbank.com/drugs/DB12669
    Investigational

    4SC-203 has been used in trials studying the treatment of Acute Myeloid Leukemia.